Solid quarter, nothing exciting from a sales perspective....

Solid quarter, nothing exciting from a sales perspective.
Margins are much better, which is good to see and provides some hope.
I still can’t figure out where the Menicon revenue goes though?
All the revenue appears to be linked to US ECP’s, every single quarter.
And yet we hear about Menicon from posters and the company regularly, but no sales / revenue?
If sounds like Menicon want to expand the relationship into new territories, which is good.
Do they pay us a licence fee per territory? $50k or $100k per country, per year?
Would seem like a fair outcome given we paid for all the R&D and the trials.
Anyway, would love some more transparency on Menicon revenues, license fees, etc.
Very hard to quantify the expansion of the relationship if we don’t know what it’s producing now.
Could be important for people exercising their entitlement rights, it will be for me.